Patient characteristics
| . | N (%) (N = 66) . |
|---|---|
| Sex (male) | 57 (86) |
| Age, median, IQR, y | 68.3 (61.2, 75.5) |
| Age groups | |
| <60 y | 15 (23) |
| 60 y to <75 y | 33 (50) |
| ≥75 y | 18 (27) |
| Prior neoplasms | |
| Myeloid disease | 10 (15) |
| Non-melanoma skin cancer | 11 (17) |
| Other solid cancer | 11 (17) |
| ECOG∗ | |
| 0 | 43 (66) |
| 1 | 21 (32) |
| 2 | 1 (2) |
| UV exposure† | |
| High | 30 (51) |
| Low | 29 (49) |
| Cytogenetics‡ | |
| Complex karyotype | 12 (24) |
| Normal karyotype | 34 (68) |
| Other | 4 (8) |
| First treatment | |
| Tagraxofusp | 30 (45) |
| AML-like intensive chemotherapy regimen | 12 (18) |
| ALL-like intensive chemotherapy regimen | 12 (18) |
| Others | 12 (19) |
| Selected time intervals | |
| Diagnosis to first treatment (d, median, IQR) | 29.5 (20.0, 46.0) |
| First symptom to first treatment (d, median, IQR) | 108 (64.2, 161.0) |
| . | N (%) (N = 66) . |
|---|---|
| Sex (male) | 57 (86) |
| Age, median, IQR, y | 68.3 (61.2, 75.5) |
| Age groups | |
| <60 y | 15 (23) |
| 60 y to <75 y | 33 (50) |
| ≥75 y | 18 (27) |
| Prior neoplasms | |
| Myeloid disease | 10 (15) |
| Non-melanoma skin cancer | 11 (17) |
| Other solid cancer | 11 (17) |
| ECOG∗ | |
| 0 | 43 (66) |
| 1 | 21 (32) |
| 2 | 1 (2) |
| UV exposure† | |
| High | 30 (51) |
| Low | 29 (49) |
| Cytogenetics‡ | |
| Complex karyotype | 12 (24) |
| Normal karyotype | 34 (68) |
| Other | 4 (8) |
| First treatment | |
| Tagraxofusp | 30 (45) |
| AML-like intensive chemotherapy regimen | 12 (18) |
| ALL-like intensive chemotherapy regimen | 12 (18) |
| Others | 12 (19) |
| Selected time intervals | |
| Diagnosis to first treatment (d, median, IQR) | 29.5 (20.0, 46.0) |
| First symptom to first treatment (d, median, IQR) | 108 (64.2, 161.0) |